These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Davydova J; Le LP; Gavrikova T; Wang M; Krasnykh V; Yamamoto M Cancer Res; 2004 Jun; 64(12):4319-27. PubMed ID: 15205347 [TBL] [Abstract][Full Text] [Related]
3. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Yamamoto M; Davydova J; Wang M; Siegal GP; Krasnykh V; Vickers SM; Curiel DT Gastroenterology; 2003 Oct; 125(4):1203-18. PubMed ID: 14517802 [TBL] [Abstract][Full Text] [Related]
4. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells. He X; Liu J; Yang C; Su C; Zhou C; Zhang Q; Li L; Wu H; Liu X; Wu M; Qian Q Hum Gene Ther; 2011 Mar; 22(3):283-92. PubMed ID: 20846024 [TBL] [Abstract][Full Text] [Related]
6. Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. Ramírez PJ; Vickers SM; Ono HA; Davydova J; Takayama K; Thompson TC; Curiel DT; Bland KI; Yamamoto M Am J Surg; 2008 Apr; 195(4):481-90. PubMed ID: 18361926 [TBL] [Abstract][Full Text] [Related]
7. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer. Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341 [TBL] [Abstract][Full Text] [Related]
8. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205 [TBL] [Abstract][Full Text] [Related]
9. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd). Rocconi RP; Zhu ZB; Stoff-Khalili M; Rivera AA; Lu B; Wang M; Alvarez RD; Curiel DT; Makhija SK Gynecol Oncol; 2007 Apr; 105(1):113-21. PubMed ID: 17173958 [TBL] [Abstract][Full Text] [Related]
11. Conditionally replicative adenoviral vectors for imaging the effect of chemotherapy on pancreatic cancer cells. Kimura J; Ono HA; Kosaka T; Nagashima Y; Hirai S; Ohno S; Aoki K; Julia D; Yamamoto M; Kunisaki C; Endo I Cancer Sci; 2013 Aug; 104(8):1083-90. PubMed ID: 23679574 [TBL] [Abstract][Full Text] [Related]
12. A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect. Paupoo AA; Zhu ZB; Wang M; Rein DT; Starzinski-Powitz A; Curiel DT Hum Reprod; 2010 Aug; 25(8):2068-83. PubMed ID: 20573677 [TBL] [Abstract][Full Text] [Related]
13. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer. Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979 [TBL] [Abstract][Full Text] [Related]
14. Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy. Armstrong L; Arrington A; Han J; Gavrikova T; Brown E; Yamamoto M; Vickers SM; Davydova J Am J Surg; 2012 Nov; 204(5):741-50. PubMed ID: 22748294 [TBL] [Abstract][Full Text] [Related]
15. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792 [TBL] [Abstract][Full Text] [Related]
16. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Suzuki K; Alemany R; Yamamoto M; Curiel DT Clin Cancer Res; 2002 Nov; 8(11):3348-59. PubMed ID: 12429621 [TBL] [Abstract][Full Text] [Related]
17. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma. Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667 [TBL] [Abstract][Full Text] [Related]
18. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses. Zhu ZB; Makhija SK; Lu B; Wang M; Wang S; Takayama K; Siegal GP; Reynolds PN; Curiel DT J Thorac Oncol; 2006 Sep; 1(7):701-11. PubMed ID: 17409940 [TBL] [Abstract][Full Text] [Related]
19. Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck. Zhu ZB; Mathis JM; Makhija SK; Lu B; Wang M; Ji S; Rivera AA; Rosenthal EL; Siegal GP; Curiel DT Int J Oncol; 2007 Nov; 31(5):1213-22. PubMed ID: 17912450 [TBL] [Abstract][Full Text] [Related]